www.high5endocrinology.tv | Meeting coverage | ENDO 2022

Diabetes and obesity

ENDO 2022

Glucagon / GLP-1 agonist to treat obesity - a…

Sebastian Meyhöfer, MD

ENDO 2022

Management of hyperglycemia for hospitalized patients

Sebastian Meyhöfer, MD

ENDO 2022

ANGPTL3 - New kid on the block?

Sebastian Meyhöfer, MD

Transgender

ENDO 2022

Bone mineral density under GnRH agonists

Achim Wüsthof, MD

DSD / AGS

ENDO 2022

Complete androgen insensitivity syndrome: MRI screening…

Achim Wüsthof, MD

ENDO 2022

CRF1 receptor antagonist beneficial for adjustment of…

Achim Wüsthof, MD

Parathyroid

ENDO 2022

Update: Guideline on hypoparathyroidism 2022

Heide Siggelkow, MD

ENDO 2022

Update: Guideline on hyperparathyroidism 2022

Heide Siggelkow, MD

Neuroendocrinology and pituitary

ENDO 2022

Central diabetes insipidus from a patient's perspective

Ilonka Kreitschmann-Andermahr, MD

ENDO 2022

Weight trajectory as a predictor of cushing’s disease

Ilonka Kreitschmann-Andermahr, MD

ENDO 2022

Addiction to wireless mobile device and obesity

Ilonka Kreitschmann-Andermahr, MD

Calcium and bone

ENDO 2022

Iron and phosphate metabolism

Heide Siggelkow, MD